Αρχειοθήκη ιστολογίου

Δευτέρα 4 Δεκεμβρίου 2017

Obinutuzumab Effective in Follicular Lymphoma, but at a Cost [News in Brief]

In a phase III trial involving more than 1,200 patients with follicular lymphoma, obinutuzumab plus chemotherapy reduced the risk of disease progression, relapse, or death by 34% compared with rituximab plus chemotherapy. However, patients receiving obinutuzumab experienced more serious side effects than those receiving rituximab.



from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2ArtmRC

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου